ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM (IBRX)

🌐 Seeking Alpha —
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM (IBRX)

AI Summary

ImmunityBio is exploring opportunities beyond bladder cancer, targeting a potentially multibillion-dollar market for solid tumors. This strategic shift may position the company strongly in the oncology sector.

Markets Deals Health ImmunityBio oncology bladder cancer solid tumor market opportunity

Read original source →